Enzolytics supports Sagaliam in disputing NIKA's false claims over HIV/AIDS immunotherapy patents.

Enzolytics Inc. backs Sagaliam Acquisition Corp's efforts to disprove NIKA Pharmaceutical's false claims over patents related to HIV/AIDS immunotherapy treatment. NIKA's CEO, Dimtar Savov, allegedly misrepresents rights to patents issued to Harry H. Zhabilov and the Zhabilov Trust. Sagaliam, as the exclusive license holder, aims to put an end to these misleading claims and safeguard both companies' shareholder value.